1st Quarter - Report

SQUIRE PATTON BOGGS for RANBAXY INC.

Firm
Client
Income
$180,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; H.R. 3630, the Middle Class Tax Relief Job Creation Act; Prescription Drug User Fee Reauthorization issues.

Foreign entity interest: Ranbaxy Labs Limited -- Interests are same as Registrant.

LobbyistCovered position, as disclosed
KENDALL BYRUM HUSSEY SenHealthLaborPensionCom2005-08
JOHN JONAS —
ERIC RASMUSSEN SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000
MATTHEW TODD TUTEN RepMichaelBilirakis91-92;93-95;98-01
ANURAG VARMA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 27 (112th), H.R. 1483 (112th), H.R. 3630 (112th)

Pharmacy PHA

S. 27, Preserve Access to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; H.R. 3630, the Middle Class Tax Relief and Job Creation Act; Prescription Drug User Fee Reauthorization issues.

Foreign entity interest: Ranbaxy Labs Limited - Interests are same as Registrant.

LobbyistCovered position, as disclosed
KENDALL BYRUM HUSSEY SenHealthLaborPensionCom2005-08
JOHN JONAS —
ERIC RASMUSSEN SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000
MATTHEW TODD TUTEN RepMichaelBilirakis91-92;93-95;98-01
ANURAG VARMA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 27 (112th), H.R. 1483 (112th), H.R. 3630 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.